Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics


Zynerba Pharmaceuticals, Inc. (ZYNE): $0.98

0.06 (+6.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZYNE Stock Price Chart Interactive Chart >

Price chart for ZYNE

ZYNE Price/Volume Stats

Current price $0.98 52-week high $6.07
Prev. close $0.92 52-week low $0.84
Day low $0.89 Volume 177,900
Day high $0.99 Avg. volume 439,023
50-day MA $1.56 Dividend yield N/A
200-day MA $2.95 Market Cap 42.72M

Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio


Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.


ZYNE Latest News Stream


Event/Time News Detail
Loading, please wait...

ZYNE Latest Social Stream


Loading social stream, please wait...

View Full ZYNE Social Stream

Latest ZYNE News From Around the Web

Below are the latest news stories about Zynerba Pharmaceuticals Inc that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.

Companies Like Zynerba Pharmaceuticals (NASDAQ:ZYNE) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | February 22, 2022

Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer

DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Legal Officer and Corporate Secretary. He will assume the duties of Suzanne Hanlon who will retire fro

Yahoo | February 15, 2022

Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference

DEVON, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will virtually present a company overview during the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 a.m. ET. Investors interested in arranging a

Yahoo | February 10, 2022

Ladenburg Thalmann & Co. Keeps a Buy Rating on Zynerba Pharmaceuticals (ZYNE)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Zynerba Pharmaceuticals (ZYNE – Research Report), with a price target of $8.00. The company's shares closed last Wednesday at $2.68. According to TipRanks.com, Higgins is a 4-star analyst with an average return of 5.7% and a 32.3% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Armata Pharmaceuticals, and Rhythm Pharmaceuticals. Zynerba Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $8.50, representing a 193.1% upside. In a report released yesterday, H.C.

Brian Anderson on TipRanks | January 6, 2022

Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

DEVON, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present during the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. A webcast of the presentation will be available on-demand beginning

Yahoo | January 6, 2022

Read More 'ZYNE' Stories Here

ZYNE Price Returns

1-mo -30.50%
3-mo -57.58%
6-mo -72.78%
1-year -81.23%
3-year -92.56%
5-year -94.84%
YTD -65.97%
2021 -12.73%
2020 -45.36%
2019 103.37%
2018 -76.28%
2017 -19.69%

Continue Researching ZYNE

Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:

Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5676 seconds.